Journal Logo

Research Article: Observational Study

Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options

A retrospective single-center study

Kian, Waleed MDa,∗; Zemel, Melanie MSb; Kestenbaum, Emily H. BSb; Rouvinov, Keren MDa; Alguayn, Wafeek MDc; Levitas, Dina MDa; Ievko, Anna MDa; Michlin, Regina MDa; Abod, Moataz A. MDc; Massalha, Ismaell MDa; Chernomordikov, Elena MDa; Sharb, Adam A. MDc; Shalata, Walid MDa; Levison, Esther BSb; Roisman, Laila C. PhDd; Lavrenkov, Konstantin MDa; Peled, Nir MD, PhDd; Nesher, Lior MDe; Yakobson, Alexander MDa

Editor(s): Cruz., Jorddy Neves

Author Information
doi: 10.1097/MD.0000000000028561
  • Open


1 Introduction

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) originated in Wuhan, China at the end of 2019. Since then, it has spread worldwide and infected hundreds of millions of people with millions of reported deaths.[1] COVID-19 infects all age groups however there is a higher prevalence of severe disease in the elderly and those with comorbid conditions.[2] Pregnancy, poor glycemic control, and cancer are associated with an increased susceptibility to acquiring COVID-19 and worse outcomes.[3–5] Specifically, cancer patients have poorer outcomes and increased admittance to the intensive care unit (ICU) after contracting the disease compared with the general population (39% vs 8% respectively; P = .0003).[6] In addition, cancer patients who underwent either surgery or chemotherapy within a month before infection had a significantly higher risk of severe adverse events than cancer patients who did not (OR 5.34, 95% CI 1.80–16.18, P = .0026).[4]

Currently, there are numerous cancer treatment options, including immune checkpoint inhibitors (ICIs), chemotherapy, target therapy and radiation therapy. ICIs are a leading form of cancer treatment that blocks several different proteins involved in cancer cells’ evasion of the immune system, allowing for the antitumor response to reactivate. These proteins include programmed cell death protein 1, programmed death ligand 1 and cytotoxic T-lymphocyte associated protein 4. ICIs are approved by the Food and Drug Administration for numerous types of malignancies such as non-small cell lung cancer, melanoma, breast cancer and others.[7] Gambichler et al demonstrated that ICI therapy was not an independent risk factor for COVID-19 susceptibility in cancer patients.[8] Another mainstay of treatment for most cancers includes chemotherapy. In addition to its toxic systemic side effects, patients undergoing active chemotherapy treatment displayed an increased risk of death from COVID-19 infection in a multicenter retrospective cohort study of 205 patients in China.[9] Target therapy and radiation therapy are other common treatments used for various cancers, however they were not associated with increased severity of disease or fatality.[10]

The BNT162b2 mRNA COVID-19 vaccine is considered one of the most promising means for combating the COVID-19 pandemic. Towards the end of 2020, the BNT162b2 mRNA COVID-19 vaccines became available and distributed worldwide. The currently used two-dose mRNA-based vaccine encodes the coronavirus spike glycoprotein that mediates attachment to host cells. The safety of this vaccine has been studied and has been shown to produce mild to moderate side effects in more than half of the participants in a phase 1, dose-escalation, open-label trial that included 45 healthy adults. The most common of which were pain at the injection site, fatigue, headache, chills, and myalgia. These systemic side effects were even more common after the second dose of the vaccine; however, severe side effects were uncommon following either dose.[11]

Cancer patients are a crucial population to protect against the virus due to the increased risk of contracting COVID-19 and developing worse outcomes following the disease. However, to date, no studies have examined the safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients, particularly ones that are undergoing treatment. Most cancer therapies alter the immune system's response to both pathogens and vaccines. This has been demonstrated when examining the immune response to the seasonal influenza vaccine. Chemotherapy has been shown to diminish the desired immunogenicity of the vaccine while ICI therapy, in itself, leads to a more robust immune response and has not been shown to alter the efficacy of the vaccine or lead to more severe side effects.[12]

With this in mind, we performed the following retrospective single center study to assess the safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients that are undergoing treatment with ICIs, chemotherapy, targeted-therapy and/or radiation.

2 Methods

2.1 Study design

Retrospective single center study examining cancer patients from Soroka University Medical Center in Israel that assesses the safety of the BNT162b2 mRNA COVID-19 vaccine. Due to the lack of information about the vaccine safety, hospital protocol dictated close monitoring of vaccinated oncological patients by their treating physician. Physicians then documented any side effects, or any suspected treatment related adverse events following the BNT162b2 mRNA COVID-19 vaccine. This study reports on any side effects taking place after the administration of the first or second dose of the BNT162b2 mRNA COVID-19 vaccine. We also report if the BNT162b2 mRNA COVID-19 vaccine exacerbated any known side effects of numerus oncologic treatments. Side effects from the vaccine were graded based on a previously described scale.[13] Adverse events from cancer therapy were graded according to the Common Terminology Criteria for Adverse Events. Pearson's Chi-Squared analysis was performed to identify differences in groups that reported or did not report any side effects. P values less than .05 were considered statistically significant. Statistics were done and the data was analyzed using IBM SPSS Statistics 26.0.

2.2 Ethics

This trial was conducted in accordance with the declaration of Helsinki and approved by Soroka University Medical Center ethics committee Sor-0016-21.

2.3 Participants

We collected data on patients with a confirmed malignancy that are currently being treated or planned to be treated at Soroka University Medical Center. Eligible patients were

  • 1. 16 years or older with a confirmed malignancy,
  • 2. actively being treated with chemotherapy, immune checkpoint inhibitors, target therapy or radiotherapy,
  • 3. planned to be treated with chemotherapy, immune checkpoint inhibitors, target therapy or radiotherapy and
  • 4. had received the BNT162b2 mRNA COVID-19 vaccine.

Patients were divided into the following groups: participants who received the vaccine (A) while on or (B) prior to antineoplastic therapy.

3 Results

We identified 210 patients who were vaccinated between December 20, 2020 (first date of vaccine availability) and April 30, 2021. A wide range of malignancies were included in this study with most solid malignancies being represented (Table 1).

Table 1 - Demographics of participants in study. Participants that developed vaccine related side effects are also noted.
Characteristics No. of patients (%) (N = 210) No. Patients with vaccine side effects (%) (N = 65)
 Years 69 ± 11 65.2 ± 11
 Male 136 (64.8) 35 (25.7)
 Female 74 (35.2) 30 (40.5)
 Yes 47 (22.4) 14 (29.8)
 No 163 (77.6) 51 (31.1)
 1 13 (6.2) 3 (23.1)
 2 22 (10.5) 11 (50.0)
 3 24 (11.4) 10 (41.7)
 4 151 (71.9) 41 (27.2)
Treatment protocol
 Chemotherapy 42 (20.0) 16 (38.1)
 Immunotherapy 48 (22.9) 12 (25.0)
 Biological 24 (11.4) 9 (37.5)
 Chemoimmunotherapy 20 (9.5) 9 (45.0)
 Immuno-biological 9 (4.3) 4 (44.4)
 Hormonal 43 (20.5) 7 (16.3)
 Radiotherapy 3 (1.4) 2 (66.7)
 Chemoradiotherapy 2 (1.0) 1 (50)
 Immuno-radiotherapy 3 (1.4) 0 (0)
 Chemo-biological 16 (7.6) 5 (31.3)
 Radio-hormonal 1 (0.5) 0 (0)
 Lung cancer
  NSCLC 35 (16.6) 11 (31.4)
  Small cell lung Ca 5 (2.4) 1 (20.0)
 Skin cancer
  Melanoma 27 (12.9) 8 (29.6)
  Basal cell Ca 6 (2.9) 1 (16.7)
  Squamous cell Ca 3 (1.4) 0 (0)
  Merkel cell Ca 1 (0.5) 0 (0)
  Kaposi sarcoma 4 (1.9) 2 (50)
  Epithelioid hemangioendothelioma 1 (0.5) 1 (100)
  Breast 29 (13.8) 12 (41.4)
  Ovarian 4 (1.9) 1 (25.0)
  Endometrial 1 (0.5) 1 (100)
  Fallopian tube 1 (0.5) 1 (100)
  Prostate 43 (20.5) 7 (16.3)
  Seminoma 1 (0.5) 1 (100)
  Renal cell Ca 17 (8.1) 7 (41.2)
  Transitional cell Ca 7 (3.3) 0 (0)
  Esophageal 1 (0.5) 0 (0)
  Gastric 10 (4.8) 2 (20.0)
  GIST 1 (0.5) 0 (0)
  Gastric signet ring 1 (0.5) 0 (0)
  Colon Ca 12 (5.7) 6 (50.0)
  Rectal 3 (1.4) 0 (0)
  Hepatocellular Ca 1 (0.5) 1 (100)
  Pancreatic Ca 2 (1.0) 1 (50.0)
  Medullary thyroid 1 (0.5) 0 (0)
  Parotid glad SCC 1 (0.5) 1 (100)
  GBM 1 (0.5) 0 (0)
  CLL 1 (0.5) 0 (0)
  Follicular lymphoma 1 (0.5) 0 (0)
1 patient received chemotherapy and hormonal therapy for 2 different primaries.
9 patients had 2 primary cancers and 1 patient had 3 primary cancers.
Percentage of patients with side effects by characteristic.

The average age of patients enrolled was 69 ± 11 with 136 (64.8%) participants being male and 74 (35.2%) participants being female. Of the 65 (31%) participants that experienced side effects, the average age was 65.2 ± 11, with 35 (25.7%) participants being male and 30 (40.5%) were female. Females reported experiencing significantly more side effects than males (P = .027, Table 3). Only 47 (22.4%) participants reported a history of allergic reactions, to either medication, food, or both, and of those 14 (29.8%) experienced a side effect following the vaccine. However, of the 163 (77.6%) participants that did not have a prior allergic reaction, 51 (31.1%) experienced a side effects to the vaccine.

Treatment protocols differed between participants and included chemotherapy, immunotherapy, biologics, hormonal therapy, and radiotherapy, along with combination therapy. Treatment protocol did not show to have an effect on the development of any side effects (P = .202). Forty two participants were on chemotherapy and 16 of those developed side effects. Forty eight participants were on immunotherapy and 24 were on biologic treatment, however only 12 and 9 of the participants on immunotherapy and biologic therapy, respectively, experienced any side effects. Forty three participants were on hormonal therapy and 3 were on radiotherapy and only 7 and 2 participants experienced side effects while on hormonal or radiotherapy, respectively. Of the combination treatment protocols, 20 patients received chemo-immunotherapy, 9 immuno-biological and 3 were on immuno-radiotherapy. Of those, 9, 4, and 0 participants experienced side effects, respectively. Participants in each treatment protocol can be seen in Table 1.

One hundred sixty eight participants were on antineoplastic treatment at the time of vaccination (arm A) and 42 participants were vaccinated prior to the start of any therapy (arm B). For patients in arm A, 49 experienced any vaccine related side effects, of which, 30 and 31 patients demonstrated side effects following the 1st or 2nd vaccination, respectively (Fig. 1 and Table 2). In arm B, only 16 participants experienced any vaccine related side effects with 11 of these demonstrating side effects following either dose (Fig. 1, Table 2).

Figure 1:
Patient allocation divided by time of vaccine administration in relation with initiation of systemic treatment.
Table 2 - Side effects based on timing of vaccination.
All enrolled patients no. (%) (N = 210) Enrolled patients with vaccine side effects no. (%) (N = 65)
Received vaccine
 On long term systemic therapy (Ongoing) 152 (72.4) 45 (29.6)
 Within 1 mo of therapy (New) 34 (16.2) 11 (32.4)
 Prior to therapy (Prior) 24 (11.4) 9 (37.5)
Underwent radiation
 Within 1 mo of vaccine 25 (11.9) 10 (40.0)
 ≥1 mo after vaccine 12 (5.7) 5 (41.7)
 Therapy AE worsened 18 (8.6) 11 (61.1)
 Therapy delay 10 (4.8) 9 (90.0)
 Hospitalization 6 (2.9) 6 (100)
 Death 4 (1.9) 4 (100)
Number of patients that experiences side effects after being split into ongoing, new and prior groups.
3 patients died from disease progression and 1 due to unknown causes.
Percentage of patients with side effects by group.

However, there was no significant difference between when the participant received the vaccine and the onset of side effects (P = .653, Table 3). Of the 9 participants that received the vaccine prior to start of therapy, 7 of them were on a treatment protocol that included chemotherapy. Additionally, 18 participants experienced adverse events that were related to their oncologic therapy and of those 11 also experienced vaccine side effects (Table 2). Therapy delay occurred in 10 participants and 9 of those also experienced side effects from the vaccine. 6 participants were hospitalized during the study period and 4 participants died.

Table 3 - Group differences in vaccine side effects.
Number of participants P value
Immunotherapy 80 .942
Non immunotherapy 130
Vaccine on long term therapy 152 .653
Vaccine within 1 mo. of therapy 34
Vaccine prior to therapy 24
Males (with side effects) 136 (35) .027
Females (with side effects) 74 (30)
Chi-Squared analysis showed no difference in observed side effects when comparing immunotherapy treatment to nonimmunotherapy treatment or when comparing the time of administration of the vaccine in relation to initiation of oncologic therapy. Chi-Squared analysis demonstrated a significant difference between genders when reporting side effects.

65 (31%) participants experienced side effects from the vaccine. Of the side effects, most were grade 1 or grade 2 (n = 64) with the most prominent side effects described being pain at injection site (n = 30) after the first dose (Table 4). One patient experienced grade 3 to 4 fatigue following the first dose (Table 4). Following the second dose of the vaccine, the most participants again described grade 1 to 2 side effects (n = 61) with the most prominent side effect being injection site pain (n = 18) and fatigue (n = 18). 4 (1.9%) participants experienced grade 3 to 4 fatigue following the second dose (Table 4).

Table 4 - Side effects following each dose of the BNT162b2 mRNA Covid-19 vaccine.
Number of patients (%)
Dose 1 Dose 2
Side effects of coronavirus vaccine (N = 65) Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Injection site
 Pain 30 (46.2) 18 (27.7)
 Erythema 1 (1.5) 2 (3.1)
 Edema/Induration 1 (1.5) 2 (3.1)
 Pruritis 2 (3.1) 1 (1.5)
Headache 2 (3.1)
Myalgia 3 (4.6) 3 (4.6)
Arthralgia 1 (1.5) 2 (3.1)
Chills 2 (3.1) 9 (13.8)
Diarrhea 1 (1.5)
Fever 1 (1.5) 7 (10.8)
Fatigue 12 (18.5) 1 (1.5) 18 (27.7) 4 (6.2)
Dysarthria 1 (1.5)
Cough 2 (3.1)
Sore throat 2 (3.1)
Lymphadenopathy 1 (1.5)
Weakness 1 (1.5) 1 (1.5)
Allergic reaction

4 Discussion

To the best of our knowledge, this is the first reported study to look at the safety of the BNT162b2 mRNA COVID-19 vaccine specifically within the cancer population. Both doses of the vaccine were generally well tolerated regardless of individual treatment protocol. The overall incidence of any side effects following either dose was 31.0% (n = 65). This value is similar to previously reported safety data which determined the incidence for side effects within the general population to be 27%, in a phase 3 trial enrolling 43,548 participants.[13] Women tended to report side effects significantly more frequently than males (P = .027). This phenomenon has been reported following the H1N1 vaccine.[14] Potential reasons include more frequent reporting or development of side effects following vaccines in women.[15,16] A recently published prospective study of healthcare workers in South Korea showed no difference in frequency of side effects between genders with the BNT162b2 mRNA COVID-19 vaccine.[17] However, their study included a vastly different population and the results cannot be generalized to oncologic patients.

The most reported local side effect was mild to moderate pain at the injection site (1st dose: n = 30; 2nd dose: n = 18). However, only 14% and 8.6% of participants reported pain at the injection site following either the first or second dose of the vaccine, respectively. These values are much lower than recently published side effect data in participants 55 years or older (71% following 1st dose, 66% following second dose).[13] The most commonly reported systemic side effects included mild to moderate chills (1st dose: n = 2; 2nd dose: n = 9) and fatigue (1st dose: n = 12; 2nd dose: n = 18). Systemic side effects are more frequently reported following the second dose in the general population and this trend is also seen in our study.[13]

Treatment protocol did not show to have effect on developing side effects (P = .202, Table 3). Interestingly, patients on immunotherapy did not have more side effects than patients on all other treatments, even though an exaggerated immune response was predicted with this treatment (P = .942, Table 3).

At the data cutoff date, only 2 patients were diagnosed with covid-19 after administration of the vaccine. Neither of these patients reported any side effects to the vaccine and serum antibody levels to the vaccine were never checked. One patient was infected 8 days following only the 1st dose while the second patient was infected 2 days following the second dose. Both of these patients were not considered fully vaccinated as the peak antibody response is shown to be approximately 2 weeks after the second dose.[18] These infections, despite immunization, raises the question of if cancer patients are able to develop a substantial immune response to the BNT162b2 mRNA COVID-19 vaccine. A recently published prospective study showed decreased efficacy of the vaccine in cancer patients actively undergoing treatment.[19] Decreased immune response to vaccines in oncology patients has also already been demonstrated with different seasonal vaccinations.[20–22] Even though these patients were not considered to be fully vaccinated, the efficacy of the vaccine in oncologic patients’ needs to be further evaluated.

Only 6 patients included in this study were hospitalized for exacerbation of known oncologic treatment related adverse events. These oncologic treatments related adverse events included, neutropenic fever, interstitial lung disease, pancytopenia and durvalumab induced immune thrombocytopenia. Three hospitalized patients received the vaccine prior to treatment, 1 received the vaccine within the same month and 1 was on long term therapy. The last hospitalized participant completed 2 years of immunotherapy for metastatic uveal melanoma 15 months prior to the vaccine. Since immunotherapy is known to have long lasting effects, it is plausible that the patient developed an exaggerated immune response to the vaccine due to the immunotherapy. Even though patients with allergies have been linked to having a higher rate of side effects following the vaccine, none of the hospitalized patients in our study had any known prior allergies.[23] The length of hospitalization ranged from 3 days to 21 days. The hospitalized patients also experienced a delay in therapy that ranged from 7 days to a complete stop in treatment with many of them requiring a dose reduction as well.

4 (1.9%) participants died during the study period. Three of these participants died due to disease progression including, 2 with metastatic melanoma and 1 with metastatic prostate cancer. The last participant received the second dose of the vaccine 15 days prior to initiation of immuno-biologic (Atezolizumab and Bevacizumab) treatment for metastatic hepatocellular carcinoma. On the following day, the participant was admitted to the hospital with grade 3 weakness, abdominal pain, nausea, and vomiting. While hospitalized for 14 days, the patient's condition further deteriorated until they eventually died.

The main limitation of this study is the potential for recall and reporting bias due to the means of data collection. This could have resulted in overestimation or underestimation of the frequency and severity of side effects. Since at the time, little safety information was known, hospital protocol dictated this reporting method. To reduce recall bias, future studies could use a questioner or another standardized data collection method to encompass all currently known side effects from the vaccine. However, this bias may alter only the minor side effects as, all major events including admissions, delay of therapy or death were captured. Thus, our conclusion that the vaccine is safe is not changed by this bias. Another limitation is the unequal gender composition of the participants. Almost double the number of males were included in the study. However, females reported side effects significantly more frequently than males. The unequal sample size could skew this finding. Larger studies with equal groups that are designed to evaluate gender differences should be done to further comment on any differences that may exist. However, the vaccine was found to be safe in both genders and the sample size difference does not alter our conclusion.

5 Conclusions

Overall, this retrospective cohort study demonstrated that the BNT162b2 mRNA COVID-19 vaccine was safe in cancer patients. The side effects were similar to those previously reported within the general population. Although larger studies focusing on both efficacy and safety need to be completed, we believe that it is safe and advantageous for cancer patients to receive the vaccine.

Author contributions

Conceptualization: Waleed Kian, Melanie Zemel, Keren Rouvinov, Moataz A Abod, Ismaell Massalha, Elena Chernomordikov, Adam A. Sharb, Walid Shalata, Laila C Roisman, Konstantin Lavrenkov, Nir Peled, Lior Nesher, Alexander Yakobson.

Data curation: Waleed Kian, Melanie Zemel, Emily H Kestenbaum, Keren Rouvinov, Dina Levitas, Anna Ievko, Regina Michlin, Moataz A Abod, Ismaell Massalha, Elena Chernomordikov, Adam A. Sharb, Walid Shalata, Laila C Roisman, Konstantin Lavrenkov, Nir Peled, Lior Nesher, Alexander Yakobson.

Formal analysis: Waleed Kian, Melanie Zemel, Emily H Kestenbaum, Keren Rouvinov, Wafeek Alguayn, Dina Levitas, Regina Michlin, Moataz A Abod, Ismaell Massalha, Elena Chernomordikov, Adam A. Sharb, Walid Shalata, Esther Levison, Laila C Roisman, Konstantin Lavrenkov, Nir Peled, Lior Nesher, Alexander Yakobson.

Investigation: Waleed Kian, Nir Peled, Alexander Yakobson.

Methodology: Waleed Kian, Nir Peled, Alexander Yakobson.

Project administration: Waleed Kian, Alexander Yakobson.

Supervision: Waleed Kian.

Visualization: Waleed Kian, Nir Peled, Lior Nesher, Alexander Yakobson.

Writing – original draft: Waleed Kian, Melanie Zemel, Emily H Kestenbaum, Keren Rouvinov, Wafeek Alguayn, Dina Levitas, Anna Ievko, Regina Michlin, Moataz A Abod, Ismaell Massalha, Elena Chernomordikov, Adam A. Sharb, Walid Shalata, Laila C Roisman, Konstantin Lavrenkov, Nir Peled, Lior Nesher, Alexander Yakobson.

Writing – review & editing: Waleed Kian, Melanie Zemel, Wafeek Alguayn, Dina Levitas, Anna Ievko, Regina Michlin, Moataz A Abod, Ismaell Massalha, Elena Chernomordikov, Adam A. Sharb, Walid Shalata, Esther Levison, Laila C Roisman, Konstantin Lavrenkov, Nir Peled, Lior Nesher, Alexander Yakobson.


[1]. WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. Available from: Accessed January 15, 2021.
[2]. Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020;2:1069–76. [cited 2021 Jan 15]. Available from: /pmc/articles/PMC7314621/?report=Abstract.
[3]. Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020;31:1068–77.
[4]. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol Lancet Publishing Group 2020;21:335–7.
[5]. Dashraath P, Wong JLJ, Lim MXK, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol 2020;222:521–31.
[6]. Ammor YM, Kaitouni ZI, Darfaoui M, Lalya I, Elomrani A, Khouchani M. Managing cancer patients during COVID-19 pandemic: a North African Oncological center experience. Pan Afr Med J 2020;35:144.
[7]. Du Rusquec P, De Calbiac O, Robert M, Campone M, Frenel JS. Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. Cancer Manag Res 2019;11:4297–312. [cited 2021 Jan 2]. Available from: /pmc/articles/PMC6527794/?report=Abstract.
[8]. Gambichler T, Reuther J, Scheel CH, Becker JC. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. J Immunother Cancer 2020;8:e001145.
[9]. Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21:904–13.
[10]. Lee LYW, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020;395:1919–26.
[11]. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med 2020;383:1920–31. [cited 2021 Jan 14]. Available from: /pmc/articles/PMC7377258/?report=Abstract.
[12]. Chong CR, Park VJ, Cohen B, Postow MA, Wolchok JD, Kamboj M. Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis 2020;70:193–9. [cited 2021 Jan 14]. Available from: /pmc/articles/PMC6938975/?report=Abstract.
[13]. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15.
[14]. Halsey NA, Griffioen M, Dreskin SC, et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Vaccine 2013;31:6107–12.
[15]. Tadount F, Doyon-Plourde P, Rafferty E, MacDonald S, Sadarangani M, Quach C. Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females? – A systematic review. Vaccine Elsevier Ltd 2020;38:444–59.
[16]. Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA 2021;325:780–1.
[17]. Bae S, Lee YW, Lim SY, et al. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci 2021;36:e115.
[18]. Roest S, Hoek RAS, Manintveld OC. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412–23.
[19]. Monin L, Laing AG, Muñoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol 2021;22:765–78.
[20]. Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 1993;12:778–82.
[21]. Mazza JJ, Yale SH, Arrowood JR, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005;3:214–20.
[22]. Toyooka S, Carbone M, Toyooka KO, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002;19:71–8.
[23]. Banerji A, Wolfson AR, Wickner PG, et al. COVID-19 vaccination in patients with reported allergic reactions: updated evidence and suggested approach. J Allergy Clin Immunol Pract [Internet] 2021;9:2135–8.

BNT162b2 mRNA; cancer; chemotherapy; COVID-19; immune checkpoint inhibitors; vaccine safety

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.